|Bid||35.75 x 300|
|Ask||36.77 x 100|
|Day's Range||35.78 - 36.70|
|52 Week Range||15.28 - 45.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.20|
Shares of companies developing therapies using the gene-editing technology Crispr declined Monday following the publication of research suggesting Crispr could cause far more extensive DNA damage than previously thought, leading to potentially harmful health effects for patients. The study, published in the journal Nature Biotechnology, said the changes were often at places far away from the intentional edit, and so went undetected in previous studies, which typically observed smaller sections of genetic material. The latest paper adds to a growing body of research highlighting obstacles in developing the gene-editing technology, which has generated public interest and huge investment as a method that could potentially treat intractable genetic diseases.
Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause unexpected genetic damage which could lead to dangerous changes in some cells. The findings, published in the journal Nature Biotechnology on Monday, have safety implications for gene therapies that are being developed using CRISPR/Cas9 - a type of molecular scissor technology that can be used to edit DNA. "We found that changes in the DNA have been seriously underestimated before now," said Allan Bradley, a professor at Britain's Wellcome Sanger Institute who co-led the research published on Monday.
This biotech has risen to the top of the CRISPR-Cas9 gene editing world. Here's how CRISPR Therapeutics did it.
MARKET PULSE Shares of companies developing CRISPR gene-editing therapies dropped in Monday morning trade after a study found that the technique can damage DNA. The research, published in the peer-reviewed journal Nature Biotechology, is just the latest questioning whether the technique brings more benefit than harms to patients, with a report in June raising the possibility that edited cells could cause cancer.
Investors are bidding up shares as the first drug candidates using the gene-editing technology inch closer to the clinic.
On Friday, July 6, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Friday's trading session in bullish territories. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: CytomX Therapeutics Inc. (NASDAQ: CTMX), Dynavax Technologies Corp. (NASDAQ: DVAX), Edge Therapeutics Inc. (NASDAQ: EDGE), Editas Medicine Inc. (NASDAQ: EDIT).
While new observations could severely limit the medical applications of gene-editing technologies, investors and companies will ultimately need more data.
Here's the story behind the biotech stock that could be the best way to profit from the discovery of the century: CRISPR-Cas9 gene editing.
NEW YORK, June 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of TrustCo ...
Shares of companies betting on the gene-editing technology known as CRISPR fell sharply on Monday after two studies in the science journal Nature Medicine questioned whether some implementations of the technique might compromise a cell’s anticancer safeguards. Editas Medicine (EDIT) dropped to $35 from $39, and Intellia Therapeutics (NTLA) slid to $24 from $27. With no products yet tested in humans, it’s hard to say whether the market has been over- or undervaluing CRISPR, a chemical tool that has revolutionized scientific research in the past decade with the ability to alter specific parts of the genetic instructions that run every cell.
CAMBRIDGE, Mass., June 13, 2018-- Editas Medicine, Inc., a leading genome editing company, today announced that it will participate in a panel and host investor meetings at the JMP Securities Life Sciences ...
Editas Medicine (EDIT) is a pharmaceutical company focused on developing therapies based on CRISPR-CAS9 gene editing technology. On June 11, EDIT stock fell ~7.8% to close at $36.15 over concerns that CRISPR CAS-9 Gene Therapy causes cancer.
Shares of gene-therapy companies sank in active trade Monday, after a STAT report that editing a cell’s genome with CRISPR/Cas9 technology might cause cancer. The STAT report said studies by scientists, which were published in Nature Medicine, found cells that had their genomes altered using the CRISPR/Cas9 method had the potential to seed tumors inside a patient. Switzerland-based CRISPR Therapeutics AG’s stock (CRSP) plunged 12.6% with volume ballooning to 8.3 million shares— almost five-times the full-day average of 1.7 million shares.
Shares in biotech stocks Crispr Therapeutics, Editas Medicine and Intellia Therapeutics fell after a scientific publication reported that gene-editing techniques might cause cancer.